JP2012532868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532868A5 JP2012532868A5 JP2012519544A JP2012519544A JP2012532868A5 JP 2012532868 A5 JP2012532868 A5 JP 2012532868A5 JP 2012519544 A JP2012519544 A JP 2012519544A JP 2012519544 A JP2012519544 A JP 2012519544A JP 2012532868 A5 JP2012532868 A5 JP 2012532868A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- aryl
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 239000002738 chelating agent Substances 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 16
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 15
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 229910021645 metal ion Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000000032 diagnostic agent Substances 0.000 claims 7
- 229940039227 diagnostic agent Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000002872 contrast media Substances 0.000 claims 4
- 230000005298 paramagnetic effect Effects 0.000 claims 3
- 101100006941 Caenorhabditis elegans sex-1 gene Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 210000003041 ligament Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005294 ferromagnetic effect Effects 0.000 claims 1
- 230000005251 gamma ray Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 210000002254 renal artery Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22394609P | 2009-07-08 | 2009-07-08 | |
| US61/223,946 | 2009-07-08 | ||
| PCT/US2010/001926 WO2011005322A2 (en) | 2009-07-08 | 2010-07-08 | N-alkoxyamide conjugates as imaging agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532868A JP2012532868A (ja) | 2012-12-20 |
| JP2012532868A5 true JP2012532868A5 (enExample) | 2013-08-29 |
| JP5676600B2 JP5676600B2 (ja) | 2015-02-25 |
Family
ID=43429724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519544A Expired - Fee Related JP5676600B2 (ja) | 2009-07-08 | 2010-07-08 | 造影剤としてのｎ−アルコキシアミド抱合体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8877157B2 (enExample) |
| EP (1) | EP2451776B1 (enExample) |
| JP (1) | JP5676600B2 (enExample) |
| CN (1) | CN102781909B (enExample) |
| AU (1) | AU2010271097B2 (enExample) |
| CA (1) | CA2803520C (enExample) |
| WO (1) | WO2011005322A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105622463B (zh) | 2006-12-26 | 2019-02-22 | 兰休斯医疗成像公司 | 用于使心脏神经支配成像的配体 |
| WO2009089022A1 (en) | 2008-01-08 | 2009-07-16 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
| AU2010271097B2 (en) | 2009-07-08 | 2015-12-10 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
| BR122020018186B1 (pt) | 2010-05-11 | 2021-07-27 | Lantheus Medical Imaging, Inc | Uso de agentes de imagiologia para preparação de uma composição para detecção do transportador de norepinefrina (net) e método para a detecção de net |
| GB201102189D0 (en) | 2011-02-08 | 2011-03-23 | King S College London | Materials and methods relating to cardiovascular imaging |
| BR122019017259B1 (pt) | 2011-09-09 | 2022-05-10 | Lantheus Medical Imaging, Inc | Compostos úteis como agentes de imageamento, composições que os compreende, métodos, e uso de agentes de imageamento |
| WO2013070471A1 (en) | 2011-11-11 | 2013-05-16 | Lantheus Medical Imaging, Inc. | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| EP3865154A4 (en) | 2018-10-10 | 2022-11-09 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE |
| CN113301920B (zh) * | 2019-01-07 | 2025-01-14 | 安斯泰来制药株式会社 | 包含配体、间隔物、肽接头和生物分子的复合物 |
| CN117486698B (zh) * | 2023-10-30 | 2025-08-19 | 国网安徽省电力有限公司电力科学研究院 | 烯醇硅醚类化合物制备c-c键偶联产物的方法与sf6的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5122885A (en) | 1974-08-13 | 1976-02-23 | Sagami Chem Res | Ashiru ll aminosan oo chikanhidorokisamidono seizohoho |
| JPS5910322B2 (ja) | 1975-07-30 | 1984-03-08 | 三井東圧化学株式会社 | 殺草剤 |
| US4859777A (en) | 1981-07-01 | 1989-08-22 | Eastman Kodak Company | Terpyridine chelating agents |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| JPH07110815B2 (ja) | 1985-11-18 | 1995-11-29 | ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム | 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤 |
| DE3768523D1 (de) | 1986-02-18 | 1991-04-18 | Squibb & Sons Inc | ((2,2,2-trichloroethoxy)methoxy)amin. |
| US5064956A (en) | 1987-06-24 | 1991-11-12 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
| IT1224627B (it) | 1988-04-12 | 1990-10-04 | Guidotti & C Spa Labor | Ammidi di acidi ciclometilen_1,2_dicarbossilici adattivita' terapeutica, procedimenti per la loro preparazione e composizioni farmaceutiche che le contengono. |
| US5087440A (en) | 1989-07-31 | 1992-02-11 | Salutar, Inc. | Heterocyclic derivatives of DTPA used for magnetic resonance imaging |
| JP2927532B2 (ja) * | 1989-11-09 | 1999-07-28 | 塩野義製薬株式会社 | 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途 |
| JPH0491070A (ja) | 1990-08-06 | 1992-03-24 | Kanebo Ltd | カリックスアレーン誘導体 |
| US5274129A (en) | 1991-06-12 | 1993-12-28 | Idaho Research Foundation, Inc. | Hydroxamic acid crown ethers |
| GB9115375D0 (en) | 1991-07-17 | 1991-09-04 | Salutar Inc | Compounds |
| US5639746A (en) | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
| TW319763B (enExample) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
| CN1203899C (zh) | 1995-06-26 | 2005-06-01 | 螯合剂有限公司 | 对第一过渡系元素具有螯合亲和力和选择性的化合物及它们在医学冶疗中的用途 |
| DE19914101C1 (de) * | 1999-03-22 | 2000-10-12 | Schering Ag | Perfluoralkylamide, ihre Herstellung und ihre Verwendung in der Diagnostik |
| US6461587B1 (en) | 1999-03-22 | 2002-10-08 | Schering Aktiengesellschaft | Perfluoroalkylamides, their production and their use in diagnosis |
| US6989139B2 (en) | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US6656448B1 (en) | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US20020002152A1 (en) * | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| IL157444A0 (en) | 2001-02-23 | 2004-03-28 | Bristol Myers Squibb Pharma Co | Labeled macrophase scavenger receptor antagonists and diagnostic and pharmaceutical compositions containing the same |
| US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
| TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
| WO2005001415A2 (en) | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| WO2005084179A2 (en) * | 2003-12-01 | 2005-09-15 | Immunomedics, Inc. | Improved method for preparing conjugates of proteins and chelating agents |
| US20070142417A1 (en) | 2005-05-11 | 2007-06-21 | Aventis Pharmaceuticals Inc | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor |
| EP1896086A1 (en) | 2005-06-30 | 2008-03-12 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| US7618957B2 (en) | 2005-07-15 | 2009-11-17 | Bayer Schering Pharma Aktiengesellschaft | Perfluoroalkyl-containing complexes, process for their production as well as their use |
| WO2009089022A1 (en) | 2008-01-08 | 2009-07-16 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
| AU2010271097B2 (en) | 2009-07-08 | 2015-12-10 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
-
2010
- 2010-07-08 AU AU2010271097A patent/AU2010271097B2/en not_active Ceased
- 2010-07-08 EP EP10797455.2A patent/EP2451776B1/en active Active
- 2010-07-08 JP JP2012519544A patent/JP5676600B2/ja not_active Expired - Fee Related
- 2010-07-08 CA CA2803520A patent/CA2803520C/en not_active Expired - Fee Related
- 2010-07-08 CN CN201080040596.8A patent/CN102781909B/zh not_active Expired - Fee Related
- 2010-07-08 US US13/382,689 patent/US8877157B2/en active Active
- 2010-07-08 WO PCT/US2010/001926 patent/WO2011005322A2/en not_active Ceased
-
2014
- 2014-09-22 US US14/492,896 patent/US9393329B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532868A5 (enExample) | ||
| US8623322B2 (en) | Non-invasive diagnostic agents and methods of diagnosing infectious disease | |
| US9546186B2 (en) | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | |
| JP6883046B2 (ja) | 長寿命ガドリニウムに基づく腫瘍標的化イメージングおよび治療薬 | |
| JP2013528161A5 (enExample) | ||
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2010526089A5 (enExample) | ||
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| JPH10512584A (ja) | 第一遷移系列元素に対してキレート化親和性および選択性のある化合物とその医療および診断への使用 | |
| JP2013513613A5 (enExample) | ||
| CN116173247A (zh) | 造影剂配制品与有关制备方法 | |
| JP2015536986A5 (enExample) | ||
| JP2016521275A5 (enExample) | ||
| JP2020502131A5 (enExample) | ||
| JP2011509294A5 (enExample) | ||
| Zhang et al. | Synthesis and biological evaluation of a novel 99mTc (CO) 3 complex of ciprofloxacin dithiocarbamate as a potential agent to target infection | |
| Haid et al. | Lower radiation burden in state of the art fluoroscopic cystography compared to direct isotope cystography in children | |
| JP2018525447A5 (enExample) | ||
| JP6789991B2 (ja) | 癌の早期骨転移の画像診断剤 | |
| JP2013507345A5 (enExample) | ||
| JP2012520855A5 (enExample) | ||
| EP2749295A1 (en) | Radiopharmaceutical and pharmaceutical kit | |
| JP6656484B2 (ja) | 放射性抗腫瘍剤 | |
| Saffari et al. | Oral administration of 99mTechnetium-labeled heparin in eosinophilic esophagitis | |
| RU2012114772A (ru) | Избирательное выявление костных метастазов при светлоклеточной почечно-клеточной карциноме |